Semaglutide and type 1 diabetes: what you need to know before asking your specialist

What the research actually shows, and where the gaps are

The evidence on GLP-1 receptor agonists in type 1 diabetes comes almost entirely from small, short-term trials and case series, not the large-scale programmes that underpin licensing decisions. A 2021 systematic review in The BMJ and related Cochrane analyses noted modest improvements in HbA1c and body weight in some studies, but the heterogeneity between trials was too wide to draw firm conclusions. No phase 3 programme comparable to STEP 1 or SURMOUNT-1 exists for semaglutide in type 1 diabetes. That absence matters. Regulatory bodies like the MHRA license medicines on the strength of that kind of evidence, and without it the risk-benefit calculation cannot be made at a population level.

The practical gap this creates is real. People living with type 1 diabetes often carry excess weight (partly because intensive insulin therapy itself promotes weight gain) and appetite suppression would be genuinely useful. The clinical interest in GLP-1 adjunct therapy is not frivolous. But usefulness in theory and safety at the individual level are different questions, and the latter depends on factors your diabetes team already holds: your current insulin regimen, your hypoglycaemia awareness, your kidney function, your carbohydrate targets.

One quick check worth doing before your specialist appointment: look at the most recent entries in your diabetes review notes for your current HbA1c and time-in-range data. Having those numbers to hand takes under a minute and gives the conversation a concrete starting point.

The hypoglycaemia and DKA risk in type 1, why it is more complex than in type 2

In type 2 diabetes, semaglutide's glucose-lowering effect is glucose-dependent, which substantially limits hypoglycaemia risk when the medicine is used alone. Type 1 diabetes is different. You are already taking exogenous insulin, and semaglutide's slowing of gastric emptying changes the timing of carbohydrate absorption in ways that are hard to predict meal to meal. That unpredictability stacks on top of the inherent variability in subcutaneous insulin absorption. The result is that insulin doses that worked reliably before may overshoot.

Euglycaemic diabetic ketoacidosis is a specific risk worth naming clearly. It occurs when ketone production rises while blood glucose stays in a range that looks reassuring, so standard sick-day rules based on high glucose alone may not catch it. Small studies of SGLT-2 inhibitors in type 1 flagged this pattern first, but GLP-1 agents may contribute through caloric restriction and reduced carbohydrate intake driven by appetite suppression. The NHS medicines page for semaglutide does not list type 1 diabetes as an indication, and any clinician considering off-label use would need to factor DKA monitoring into the care plan. That level of oversight is well beyond what a private online service can or should provide for this group.

If you want to understand how semaglutide is used within its licensed indications, our page on semaglutide and diabetes covers the type 2 evidence in full. If you are also wondering whether semaglutide is specifically intended for type 2 diabetes, we cover that question separately.

Who can prescribe semaglutide off-label for type 1, and what that process looks like

Off-label prescribing is legal in the UK and happens routinely across medicine when the clinical rationale is strong and informed consent is given. For semaglutide in type 1 diabetes, the prescriber would need to be a diabetes specialist or endocrinologist with access to your full history, not a general prescriber working from a short online questionnaire. The GMC's guidance on off-label medicines requires that the prescriber takes personal responsibility for the decision, documents it clearly, and ensures appropriate monitoring is in place. None of that is a barrier in principle; it is simply a description of what proper care requires.

A private online weight-loss service (including ours at nume) is not the right setting for this. Our prescribers review consultations for adults seeking licensed weight-management treatment; Wegovy for type 1 diabetes sits outside the scope of what we can clinically support. That is not a policy preference, it is a safety boundary. Your diabetes team, or a referral to an obesity medicine specialist who works alongside that team, is the appropriate route.

For context on what Wegovy is licensed for in the weight-management setting, and how the Wegovy pathway works for eligible adults, that information is available separately. People with type 2 diabetes and obesity do fall within the licensed indications, you can read about that on our Wegovy for type 2 diabetes page. You may also find it useful to read about whether Wegovy makes your heart beat faster, a question that comes up often for people weighing up the cardiovascular effects of starting treatment.

Pregnancy, conception, and contraception if you have type 1 diabetes

Semaglutide is not recommended during pregnancy, while breastfeeding, or when trying to conceive, this applies across all patient groups, not only type 1 diabetes. For women with type 1 diabetes the stakes around conception are already elevated, and planning pregnancy with your diabetes and obstetric teams is standard care. Adding a GLP-1 medicine into that picture without specialist input is not something any responsible prescriber would do remotely.

The MHRA advises using effective contraception during semaglutide treatment. If you are on oral contraception, it is worth discussing whether a non-oral method offers more reliable absorption, since GLP-1 agents can affect gastric emptying and therefore the timing of oral drug absorption. Our page on Wegovy and pregnancy covers the broader guidance in detail, and the NHS England weight-management injections page addresses contraception and HRT considerations specifically. If you are eligible for licensed weight-management treatment and want to explore whether that might be suitable after your family planning conversations are complete, checking your eligibility with our prescribers is the right next step.